Key Highlights
- StatLab inaugurates a 35,000 square foot histology manufacturing facility in Arlington, Texas, with potential for future expansion.
- The Arlington site adds to StatLab’s global manufacturing network, now totaling 6 locations, and introduces injection molding capabilities in the U.S.
- Acquisition of CellPath Ltd. catalyzes expansion, with plans for blow molding and glass slide manufacturing at the Arlington facility.
Source: Business Wire
Notable Quote
- “None of this would have been possible without the help of our Newtown, Wales operational and technical teams to support this key capability expansion. We are grateful for their collaboration and partnership to build on their experience spanning more than 30 years with high-quality precision injection molding.” – Dae Hong, CEO at StatLab
SoHC's Take
The opening of StatLab’s new facility in Arlington, Texas, marks a significant milestone in the company’s commitment to innovation and quality in the field of histology. By bringing essential manufacturing capabilities like injection molding to the U.S., StatLab not only enhances its operational efficiency and supply chain reliability but also demonstrates a forward-thinking approach to sustainable manufacturing practices. The addition of this state-of-the-art facility reflects StatLab’s dedication to meeting the evolving needs of the medical diagnostic community, ensuring a steady supply of high-quality histology consumables. Furthermore, the acquisition of CellPath Ltd. and the subsequent expansion into new manufacturing processes underline StatLab’s strategic growth and its role as a leader in the anatomic pathology sector. This development not only strengthens StatLab’s position in the global market but also promises to deliver greater value and innovation to customers and patients alike.
